Montreal, June 18, 2020 – The Canadian Cancer Society (CCS) and the Quebec Breast Cancer Foundation (QBCF), two leading organizations in funding breast cancer research, together with the biopharmaceutical research consortium CQDM, are proud to support the research conducted by Professor Yves St-Pierre at INRS-Institut Armand-Frappier. Valued at $1.15M, the project will support the development of next-generation immunotherapies against triple-negative … Read More
CQDM grants $1.15 M in funding to Professor Yves St-Pierre’s team to develop a revolutionary immunotherapy against breast cancer
Montreal, June 18, 2020 – CQDM partners with the Canadian Cancer Society (CCS), the Quebec Breast Cancer Foundation (QBCF), the Armand-Frappier Foundation, the Canadian Glycomics Network (GlycoNet), Zymeworks and Pfizer as part of a $1.15M funding agreement. These funds will enable Professor Yves St-Pierre and his colleagues, Professors David Chatenet and Nicolas Doucet, to advance their work on breast cancer … Read More
New call for proposals under the Fonds d’accélération des collaborations en santé
June 16th 2020 – The Government of Quebec is launching the second call for proposals under the Fonds d’accélération des collaborations en santé (FACS). Consortia of partners from the public, private and non-profit sectors are invited to submit structuring projects that meet the current and future practical needs of companies in the life sciences sector. Proposed initiatives may involve any … Read More
Mobilisation sans précédent de l’écosystème québécois de recherche et d’innovation contre la COVID-19
19 mai 2020 – Ces moments difficiles mettent notre société au défi et nous obligent à être à la hauteur du rendez-vous que l’avenir nous donne. Dans le journal Le Monde, l’historien Yuval Noah Harari a récemment écrit que « Le véritable antidote à l’épidémie n’est pas le repli, mais la coopération » et ajoute « la véritable protection vient du … Read More
Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers
May 15th – 2020 – CQDM congratulates Theratechnologies and UQAM’s Professor Borhane Annabi for the positive results presented at the Virtual Annual Meeting II of the American Association for Cancer Research (AACR), particularly those obtained with its docetaxel-peptide conjugate TH-1902 for the treatment of triple-negative breast cancer. These are very encouraging results! To read Theratechnologies press release, click here.
Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D
Quebec City, Quebec, May 5th, 2020 – The biopharmaceutical research consortium CQDM and Medicago R&D are proud to announce today the funding of a research project that will allow the Quebec City-based company to increase the competitiveness of its vaccine production platform and confirm its position as leader in the biopharmaceutical industry in Canada. Through CQDM, the Ministry of Economy and … Read More
Pre-launch of a new call for proposals in June 2020: discover the latest updates!
Fonds d’accélération des collaborations en santé (Health Collaboration Acceleration Fund) May 27th 2020 – To stimulate economic recovery in the life sciences sector, the Government of Quebec is making changes to the Fonds d’accélération des collaborations en santé (FACS) and inviting actors of the ecosystem to collaborate by launching ambitious projects that meet the practical needs of Quebec’s small and medium-sized … Read More
CQDM welcomes Zymeworks as a new member of CQDM’s biopharmaceutical consortium
Montreal, February 27, 2020 – CQDM is pleased to welcome Zymeworks Inc. as a new member of its biopharmaceutical research consortium established to identify and invest in highly innovative biopharmaceutical research projects in Quebec and Canada with the ultimate goal of enabling the development of better treatments for patients. As a CQDM member, Zymeworks will benefit from the consortium’s ability … Read More
CQDM partners with GlycoNet to support innovative Glycomics research in Canada
Montreal, Feb 25th, 2020 – CQDM and the Canadian Glycomics Network (GlycoNet) are pleased to announce they have formed a strategic partnership to identify and co-finance biopharmaceutical research projects in glycoscience across Canada.
2nd Annual Gordon Shore Prize – Postdoctoral Internships in the Biopharmaceutical Industry
Presented by CQDM, Diazon Pharmaceuticals and Mitacs, the Gordon Shore Prize is awarded to new graduates whose doctoral thesis demonstrated their research excellence in the life science field. A 6-month postdoctoral internship of $24,000 will be offered to each of the awardees by the participating Quebec-based companies: Feldan Therapeutics, Kisoji Biotechnology, Ovensa Innovations and Repare Therapeutics. To be eligible, candidates … Read More